Boston Tech - SiliconSnark

SiliconSnark robot checks AI agents at a Boston server-room security gate.

Boston Tech

Neo Raised $100 Million to Put a Bouncer on Your AI Agents

Boston cybersecurity startup Neo raised $100 million to secure AI agents with endpoint controls, software inventory, and real-time policy enforcement.

SiliconSnark robot watches Atlas sequence parts at a Boston Dynamics factory in Waltham.

Boston Tech

Hyundai Is Buying All of Boston Dynamics, Because Atlas Needs a Factory More Than Applause

Hyundai is taking full control of Waltham-based Boston Dynamics as Atlas moves from viral robot demos toward factories, manufacturing, and real work.

Mustard-yellow SiliconSnark robot teaches a wheeled factory robot beside a Cambridge lab and Boston manufacturing floor.

Boston Tech

Walden Robotics Raised $300 Million to Put Cambridge Robots on the Factory Floor

Cambridge startup Walden Robotics raised $300 million for trainable factory robots already working at Toyota, making Boston’s physical AI bet concrete.

SiliconSnark robot in Kendall Square beside a giant CPAP mask and an AD109 pill heading toward FDA review.

Boston Tech

Apnimed Got Its Sleep Apnea Pill Into FDA Review, and Cambridge Sees a CPAP Exit Ramp

Apnimed's July 14 FDA filing acceptance puts its Cambridge sleep apnea pill AD109 on track for a February 28, 2027 review decision.

SiliconSnark robot outside a Cambridge biotech office juggling an antibiotic bottle, antibodies, and financing papers.

Boston Tech

Spero Turned an Antibiotic Approval Into an Immunology Pivot, Because Cambridge Never Wastes a Receipt

Spero Therapeutics used a $105 million royalty financing and a new antibody license to turn its Utebzi approval into a Cambridge immunology reboot.

SiliconSnark robot outside Biogen in Cambridge with a giant autoinjector and home-treatment imagery.

Boston Tech

Biogen Got an At-Home Leqembi Start Approved, and Cambridge Just Shortened the Infusion Pilgrimage

FDA approved Leqembi IQLIK's at-home starting dose on July 13, giving Cambridge-based Biogen a meaningful Alzheimer's access and workflow win.

Mustard-yellow SiliconSnark robot in Kendall Square between Prime and Beam with a gene-editing legal ruling.

Boston Tech

Prime Medicine Beat Beam in Gene-Editing Arbitration, and Cambridge Called It Family Therapy

Prime Medicine's July 8 Beam ruling cleared its AATD gene-editing program, giving Cambridge biotech one more extremely local way to compete.

SiliconSnark robot outside Vertex in Boston juggling a giant biotech deal with drug assets and deal papers.

Boston Tech

Vertex Bought Crinetics for $10 Billion, Because Boston Enjoys Expensive Homework

Vertex agreed to buy Crinetics for $10 billion on July 6, giving Boston biotech a huge endocrinology bet and a fresh test beyond cystic fibrosis.

SiliconSnark robot watches Atlas deliver a match ball while Spot patrols at a World Cup stadium.

Boston Tech

Boston Dynamics Put Atlas on the World Cup Stage, Because Waltham Never Does Anything Casually

Boston Dynamics put Atlas and Spot into FIFA World Cup 2026 operations, giving Waltham robotics its biggest global stage yet.

SiliconSnark robot outside Vertex in Boston presenting a glowing CRISPR plan beside a pediatric treatment wagon.

Boston Tech

Vertex Expanded Casgevy to Age 2, and Boston's CRISPR Future Now Comes in Toddler Sizes

Vertex's July 1 FDA expansion makes Casgevy available to children ages 2 and up, a major Boston biotech milestone with real access hurdles.

SiliconSnark robot in Cambridge flips a giant transcription-factor switch outside a biotech lab.

Boston Tech

Flare Therapeutics Raised $85 Million to Drug Transcription Factors, Which Is Extremely Cambridge

Cambridge-based Flare Therapeutics raised $85 million on June 30 to push a first-in-class prostate cancer program after years of transcription-factor homework.

SiliconSnark robot rolls a glowing drug-application binder outside a Waltham biotech campus.

Boston Tech

Cogent Filed Its Third Bezuclastinib NDA, and Waltham Looks Weirdly Inevitable

Waltham-based Cogent filed an NDA for bezuclastinib in advanced systemic mastocytosis, turning a rare-disease bet into a serious 2026 launch race.

See all